Axsome Therapeutics Files 8-K

Ticker: AXSM · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1579428

Sentiment: neutral

Topics: reporting, sec-filing

Related Tickers: AXSM

TL;DR

AXSM filed a routine 8-K, no major news.

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Axsome Therapeutics, Inc. to the SEC, without detailing any specific new material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose any new material events, risks, or significant financial changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 1, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is April 01, 2025.

What is Axsome Therapeutics, Inc.'s state of incorporation?

Axsome Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Axsome Therapeutics, Inc.?

The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.

Where are Axsome Therapeutics, Inc.'s principal executive offices located?

Axsome Therapeutics, Inc.'s principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Axsome Therapeutics, Inc. (AXSM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing